The role of neoadjuvant aromatase inhibitors in ER / PR positive HER-2 neu negative in postmenopausal females with locally advanced breast cancer /
Heba Aly Mohamed Ateya
The role of neoadjuvant aromatase inhibitors in ER / PR positive HER-2 neu negative in postmenopausal females with locally advanced breast cancer / دور مثبطات الارومازين فى العلاج ما قبل الجراحة فى حالات فى حالات سرطان الثدى المتقدم موضعيا فى السيدات بعد سن الياس ذوات مستقبلات الاستروجين / البروجستيرون الموجبة والهيرتو نيو السالبة Heba Aly Mohamed Ateya ; Supervised Heba M. Elzawahry , Nadia Mahmoud Mokhtar , Osman M. Mansour - Cairo : Heba Aly Mohamed Ateya , 2013 - 188 P. ; 25cm
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Medical)
Background: In Egypt female breast cancer ranks as the first malignancy affecting females (37.5% in NCI Egypt). Approximately 20% to 25% of breast cancer patients present with locally advanced disease. Methods : this is a prospective study including fifty two female postmenopausal patients with newly diagnosed LABC, they receive 4 months of neoadjuvant aromatase inhibitor (letrozole) 2.5 mg daily followed by clinical and radiological evaluation, if they have at least partial response, they will be refered to surgery
Aromatase inhibitors locally advanced breast cancer Neoadjuvant
The role of neoadjuvant aromatase inhibitors in ER / PR positive HER-2 neu negative in postmenopausal females with locally advanced breast cancer / دور مثبطات الارومازين فى العلاج ما قبل الجراحة فى حالات فى حالات سرطان الثدى المتقدم موضعيا فى السيدات بعد سن الياس ذوات مستقبلات الاستروجين / البروجستيرون الموجبة والهيرتو نيو السالبة Heba Aly Mohamed Ateya ; Supervised Heba M. Elzawahry , Nadia Mahmoud Mokhtar , Osman M. Mansour - Cairo : Heba Aly Mohamed Ateya , 2013 - 188 P. ; 25cm
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Medical)
Background: In Egypt female breast cancer ranks as the first malignancy affecting females (37.5% in NCI Egypt). Approximately 20% to 25% of breast cancer patients present with locally advanced disease. Methods : this is a prospective study including fifty two female postmenopausal patients with newly diagnosed LABC, they receive 4 months of neoadjuvant aromatase inhibitor (letrozole) 2.5 mg daily followed by clinical and radiological evaluation, if they have at least partial response, they will be refered to surgery
Aromatase inhibitors locally advanced breast cancer Neoadjuvant